泌尿肿瘤手术风险分层中衰弱指数的比较:应选择哪种指数?
本研究基于NSQIP数据库2013至2017年接受根治性前列腺切除术、部分或根治性肾切除术或根治性膀胱切除术的101739例患者,比较改良衰弱指数(mFI)与修订版风险分析指数(RAI-Rev)对30天围手术期结局的预测能力。结果显示RAI-Rev对死亡和非居家出院的区分能力优于mFI,两者对主要围手术期并发症的区分能力相似。作者认为RAI-Rev作为衰弱预后工具可能比mFI更有用。
要点
- 在101739例泌尿肿瘤大手术患者中,RAI-Rev对死亡的区分能力(C统计量0.688-0.798)优于mFI(0.594-0.677)。
- RAI-Rev对非居家出院的区分能力(C统计量0.638-0.734)优于mFI(0.593-0.639)。
- 两种衰弱指数对主要围手术期并发症的区分能力相似(C统计量0.531-0.607)。
核心结论
- 在接受泌尿肿瘤大手术的患者中,RAI-Rev作为衰弱预后工具可能比mFI更有用。
- 探索衰弱的前瞻性研究和临床试验在设计时应考虑这些结果。
研究设计与样本
- 基于NSQIP数据库的回顾性分析,纳入2013年至2017年接受根治性前列腺切除术、部分或根治性肾切除术或根治性膀胱切除术的患者,共101739例。
- 使用多变量逻辑回归分析mFI和RAI-Rev与30天围手术期结局的关联,并用受试者工作特征曲线分析和DeLong检验比较两种工具的预测性能。
主要发现
- 30天主要并发症发生率从前列腺切除术的2.40%到膀胱切除术的26.86%不等。
- 非居家出院率范围为1.92%至13.54%,死亡率范围为0.16%至1.43%。
- RAI-Rev对死亡的区分能力(C统计量0.688-0.798)高于mFI(C统计量0.594-0.677)。
- RAI-Rev对非居家出院的区分能力(C统计量0.638-0.734)高于mFI(C统计量0.593-0.639)。
- 两种衰弱指数对主要围手术期并发症的区分能力相似(C统计量0.531-0.607)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the predictive ability of the modified Frailty Index (mFI) and the revised Risk Analysis Index (RAI-Rev) for perioperative outcomes in patients undergoing major urologic oncologic surgery, aiming to identify the optimal frailty screening tool for surgical risk stratification. METHODS: NSQIP was queried to identify patients undergoing radical prostatectomy, partial or radical nephrectomy, or radical cystectomy between 2013 and 2017. We investigated the association of mFI and RAI-Rev with the following 30-day perioperative outcomes using multivariable logistic regression: major complications, Clavien grade ≥4 complications, non-home discharge, 30-day readmission, and all-cause mortality. Receiver-operating characteristic curve analysis compared the predictive performances of the 2 frailty instruments, with differences between the C-statistics assessed using DeLong's test. RESULTS: Among 101,739 patients, 30-day major complication rates varied from 2.40% in prostatectomy to 26.86% in cystectomy, non-home discharge rates ranged from 1.92% to 13.54%, and mortality rates were between 0.16% and 1.43%. RAI-Rev showed higher discriminatory ability for mortality (C-statistic: 0.688-0.798) and non-home discharge (C-statistic: 0.638-0.734) compared to mFI (C-statistic: 0.594-0.677 and 0.593-0.639, respectively). Both frailty indices had similar discriminatory ability for major perioperative complications (C-statistic: 0.531-0.607). DeLong's test confirmed statistically significant differences in C-statistics between RAI-Rev and mFI for mortality (P <.001) and non-home discharge (P <.001) across all surgical cohorts. CONCLUSION: RAI-Rev may have greater utility as a frailty prognostic tool than mFI among patients undergoing major urologic surgery. Prospective studies and clinical trials exploring frailty should consider these results during trial design.
引用
- Deol ES, Sharma V, Fadel AE, et al. Comparing Frailty Indices for Risk Stratification in Urologic Oncology: Which Index to Choose? Urology. 2024. PMID: 39214499. doi:10.1016/j.urology.2024.08.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。